Madhur Garg is a consulting intern at MarktechPost. He has a strong passion for Machine Learning and a keen interest in artificial intelligence, focusing on its diverse applications in medicine and healthcare, particularly in oncology, immunotherapy, and hematology. Madhur's work has been featured in MarktechPost Media Inc., Red Journal, and OncLive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Madhur Garg's coverage predominately focuses on scientific and industry-specific topics within artificial intelligence, machine learning, neural networks, deep learning, and language models. The articles often cite data and are structured as press releases.
Given the technical nature of the covered themes and topics, Madhur is likely to be most receptive to pitches that provide detailed insights from experts in these fields. Pitches should highlight innovative approaches or breakthroughs in AI research with real-world applications or potential impact on industries.
Sources who have been directly involved in the development or implementation of new AI technologies are likely to capture Madhur's attention. It would also be beneficial for sources to offer access to relevant data supporting their expertise or claims related to AI advancements.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Shalom Kalnicki, Rafi Kabarriti, William R. Bodner, Keyur J. Mehta, Balazs Halmos, Madhur Garg, Adel Zakharia, Nitin Ohri
Affiliations & Notes Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY Article Info Publication History:
PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
